Sankyo Articles
Stock Commentary - Tokyo
1 August 2001
Sankyo narrows its R&D focus
1 August 2001
Japan pharma stocks - week to July 30
31 July 2001
France's Ethypharm postpones IPO
4 July 2001
Stock Commentary - Tokyo
14 June 2001
Tokyo stock comment
12 June 2001
France's Ethypharm announces listing
8 June 2001
Sankyo planning to cut 1,000 jobs
6 June 2001
Stock Commentary - Tokyo
31 May 2001
Stock Commentary - Tokyo
17 May 2001
Tokyo pharma stock market week to May 14
15 May 2001
Tokyo pharma stock market to May 7, 2001
8 May 2001
Tokyo pharma stocks week to April 30
2 May 2001
Stock Commentary - Tokyo
26 April 2001
Tokyo pharma stock market - week to April 23
25 April 2001
1st-qtr 2001 net losses surge at ArQule
24 April 2001
Stock Commentary - Tokyo
19 April 2001
Tokyo pharma stock market week to April 16
18 April 2001
Tokyo pharma stock market: week to April 9, 2001
10 April 2001
Sankyo signs $45 mill deal with X-Ceptor
10 April 2001
Tokyo pharma stock market - week to April 2
4 April 2001
Tokyo pharma stock market - week to March 26, 2001
27 March 2001
Tokyo pharma stocks in week to Monday March 19, 2001
21 March 2001
Stock Commentary - Tokyo
8 March 2001
Tokyo stock watch, week to March 5
7 March 2001
SkyePharma picked as Kowa's statin partner
12 February 2001
Stock Commentary - Tokyo
1 February 2001
Japan's Sankyo expanding in USA
23 January 2001
Japan's Sankyo to move OTC production
15 January 2001
Stock Commentary - Tokyo
11 January 2001
Stock Commentary - Tokyo
4 January 2001
Healthy harvest of New Chemical Entities in 2000
2 January 2001
Lilly, Sankyo link up on antiplatelet drug
21 December 2000
Stock Commentary - Tokyo
14 December 2000
Stock Commentary - Tokyo
7 December 2000
Sankyo, Sumitomo sign up with Incyte
5 December 2000
Mevalotin sales holding up at Sankyo
27 November 2000
Stock Commentary - Tokyo
26 October 2000
Stock Commentary Tokyo
12 October 2000
Genzyme Corp set to acquire GelTex Pharmaceuticals for $1 billion
12 September 2000
Stock Commentary Tokyo
7 September 2000
Chugai shares downgraded on concerns over product pipeline
6 September 2000
Stock Commentary Tokyo
31 August 2000
Good prospects for Ono's Elaspol; HSBC
22 August 2000
Slight slip in Tokyo pharma stocks
22 August 2000
Stock Commentary Tokyo
17 August 2000
Stock Commentary Tokyo
10 August 2000
Pravastatin shows effect in reducing stroke
1 August 2000
Sankyo seeks FDA OK for hypertension drug
1 August 2000
Stock Commentary Tokyo
20 July 2000
Stock Commentary Tokyo
13 July 2000
Sankyo looks to new drug to boost US presence
6 July 2000
Stock Commentary Tokyo
6 July 2000
Pharmagene plans London flotation
30 June 2000
Japan Lipitor launch: a threat for statins
19 June 2000
Stock Commentary Tokyo
15 June 2000
Stock Commentary Tokyo
8 June 2000
Stock Commentary Tokyo
25 May 2000
Stock Commentary Europe
25 May 2000
Takeda benefits from strong US showing
24 May 2000
Stock Commentary Tokyo
18 May 2000
Stock Commentary Tokyo
11 May 2000
Stock Commentary Tokyo
4 May 2000
W-L sets price for Lipitor in Japan
3 May 2000
Stock Commentary Tokyo
27 April 2000
Stock Commentary Tokyo
19 April 2000
Stock Commentary Tokyo
13 April 2000
Sankyo link-up with Kyowa Hakko for NK-104?
11 April 2000
Stock Commentary Tokyo
6 April 2000
Health care boosts Bayer's Japan sales
6 April 2000
Stock Commentary Tokyo
3 April 2000
Stock Commentary Tokyo
16 March 2000
Japan majors' price cuts will average 6%
13 March 2000
Stock Commentary Tokyo
9 March 2000
Sankyo discusses new COX-2 inhibitor with analysts
7 March 2000
Kirin looking to triple revenues
2 March 2000
Stock Commentary Tokyo
24 February 2000
Stock Commentary Tokyo
17 February 2000
Stock Commentary Tokyo
10 February 2000
Stock Commentary Tokyo
27 January 2000
Stock Commentary Tokyo
13 January 2000
Analysts upgrade Japanese pharmaceutical industry to overweight
11 January 2000
Busy year for NCEs as major new compound classes launched
6 January 2000
Stock Commentary Tokyo
6 January 2000
Stock Commentary Tokyo
16 December 1999
Stock Commentary Tokyo
2 December 1999
Takeda to launch Actos in Japan; $1bn drug?
2 December 1999
New plant opens in Saudi Arabia
29 November 1999
Stock Commentary Tokyo
25 November 1999
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
